NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Stock Short Interest Drops 91.8%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 38,236 shares, a drop of 91.8% from the August 31st total of 469,120 shares. Approximately 2.8% of the shares of the company are short sold. Based on an average trading volume of 40,192 shares, the days-to-cover ratio is presently 1.0 days.

NeuroSense Therapeutics Price Performance

Shares of NeuroSense Therapeutics stock remained flat at $7.40 on Thursday. 8,880 shares of the stock were exchanged, compared to its average volume of 25,171. The business has a 50 day moving average of $9.06 and a 200 day moving average of $13.20. NeuroSense Therapeutics has a 1 year low of $5.00 and a 1 year high of $26.64. The stock has a market cap of $14.06 million, a price-to-earnings ratio of -0.69 and a beta of 1.60.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned about 0.21% of NeuroSense Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 1.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NRSN shares. Weiss Ratings cut NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. HC Wainwright assumed coverage on NeuroSense Therapeutics in a research note on Thursday, September 3rd. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.00.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.